Chemed (CHE) Cost of Revenue (2009 - 2026)

Chemed (CHE) has reported Cost of Revenue for 18 consecutive years, with $441.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 2.61% year-over-year to $441.7 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 5.9% YoY), while the FY2025 annual figure was $1.7 billion, up 8.23% from the prior year.
• Cost of Revenue came in at $441.7 million for Q1 2026 at Chemed, up from $414.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $441.7 million in Q1 2026, with the low at $336.6 million in Q1 2022.
• Average Cost of Revenue over 5 years is $385.9 million, with a median of $385.1 million recorded in 2024.
• Across the five-year window, Cost of Revenue slipped 3.9% in 2022 and advanced 13.26% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $349.6 million in 2022, then gained by 2.51% to $358.3 million in 2023, then rose by 13.26% to $405.9 million in 2024, then increased by 2.04% to $414.2 million in 2025, then climbed by 6.66% to $441.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $441.7 million, $414.2 million, and $428.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.